Bli medlem
Bli medlem

Du är här

2016-11-15

Nordic Nanovector: Nordic Nanovector appoints Dr Lisa Rojkjaer, MD as Chief Medical Officer

Date: 15.11.2016        Press Release no: 56/2016

Oslo, Norway, 15 November 2016

Nordic Nanovector ASA (OSE: NANO) is pleased to announce that Lisa
Rojkjaer, MD has joined the company today as Chief Medical Officer
(CMO) and as a member of the Executive Management Team. Dr Rojkjaer
will lead all clinical development strategy and execution and support
the company's efforts to identify opportunities to expand its
pipeline of innovative targeted therapies for haematological cancers.

Dr Rojkjaer is a board-certified haematologist with more than 15 years
of global and regional clinical development and medical affairs
expertise in the biotech and pharma industries, and has extensive
experience in the development of both biologics and small molecules
in haematology and immunology. She joins Nordic Nanovector from
Novartis Pharmaceuticals where she held the position of Global
Clinical Program Head, Oncology Global Development. Her previous
roles also include CMO at Molecular Partners (Switzerland), Vice
President, Head of Clinical Development at Morphosys AG (Germany),
and Head of Global Medical Affairs, Biopharmaceuticals and Director
of Clinical Development, Hematology in the US for Novo Nordisk.

Dr Rojkjaer holds a medical degree from the University of Toronto and
received board certification in both internal medicine and
hematology.

Dr Rojkjaer commented: "I am delighted to join Nordic Nanovector at
this exciting time in its development. The company's lead candidate
Betalutin® is demonstrating in clinical studies its potential to
become an important new therapy for the treatment of NHL patients.
Its technology is also providing multiple exciting new pipeline
opportunities. I look forward to working with the management team and
contributing to the future growth of the company."

Luigi Costa, Chief Executive Officer, added: "I am very pleased to
welcome Lisa to the team. She brings on board strong expertise in
clinical development of novel cancer treatments, particularly in the
field of haematology. Lisa's knowledge and leadership will be key to
the development of Betalutin® as well as to support the growth of
Nordic Nanovector's promising pipeline."

For further information, please contact:

For Nordic Nanovector
IR enquiries:
Luigi Costa, Chief Executive Officer
Cell: +41 79 124 8601

Tone Kvåle, Chief Financial Officer
Cell: +47 91 51 95 76
Email: ir@nordicnanovector.com

Media enquiries:
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949
Email: nordicnanovector@citigatedr.co.uk

About Nordic Nanovector:
Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and
oncology. The Company's lead clinical-stage product opportunity is
Betalutin®, the first in a new class of
Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and
complement current options for the treatment of non-Hodgkin Lymphoma
(NHL). NHL is an indication with substantial unmet medical need and
orphan drug opportunities, representing a growing market worth over
$12 billion by 2018.

Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab
(previously referred to as HH1), conjugated to a low intensity
radionuclide (lutetium-177). The preliminary data has shown promising
efficacy and safety profile in an ongoing Phase 1/2 study in a
difficult-to-treat NHL patient population. The Company is aiming at
developing Betalutin® for the treatment of major types of NHL with
first regulatory submission anticipated in 1H 2019.

Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets,
while exploring potential distribution agreements in selected
geographies. The Company is committed to developing its ARC pipeline
to treat multiple selected cancer indications.

Further information about the Company can be found at
www.nordicnanovector.com

This information is subject to the disclose requirements pursuant to
section 5-12 of the Norwegian Securities Trading Act.

-----------------------------------------------------------
http://news.cision.com/nordic-nanovector/r/nordic-nanovector-appoints-dr...

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.